Search

Your search keyword '"Popat, Sanjay"' showing total 1,132 results

Search Constraints

Start Over You searched for: Author "Popat, Sanjay" Remove constraint Author: "Popat, Sanjay"
1,132 results on '"Popat, Sanjay"'

Search Results

2. MesoGraph: Automatic Profiling of Malignant Mesothelioma Subtypes from Histological Images

5. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial

7. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

9. Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer

11. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

12. The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care

14. A tailored approach to horizon scanning for cancer medicines

17. Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study

22. Malignant Mesothelioma Subtyping of Tissue Images via Sampling Driven Multiple Instance Prediction

23. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

24. Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).

25. FURVENT: Phase 3 trial of furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).

26. Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.

27. 119 Estimating the health benefits of introducing ctDNA next generation sequencing to the diagnostic pathway for advanced lung cancer: A modelling study

28. 19 Utility of blood tests after completion of maintenance durvalumab after radical chemo-radiotherapy in patients with Non Small Cell Lung Cancer stage III

29. 48 Real world outcomes of a lung cancer genomic tumour advisory board: a single-centre experience in the United Kingdom

30. 7 Concordance of MET amplification detection between FISH and NGS in NSCLC

31. 81 Evaluation of neoadjuvant chemo-immunotherapy for operable non-small cell lung cancer: clinical outcomes and impact on service delivery

32. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study

33. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial

34. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

35. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743

36. The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment: Including myocarditis and the new entity of non inflammatory left ventricular dysfunction

38. Author Correction: Integrated genomics point to immune vulnerabilities in pleural mesothelioma

41. Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

42. Malignant Mesothelioma Subtyping of Tissue Images via Sampling Driven Multiple Instance Prediction

44. Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India

45. Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report

46. Liquid biopsies for faster diagnosis of suspected advanced pancreatic and biliary tract cancers: ACCESS, a UK innovation programme.

47. Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade

48. Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

Catalog

Books, media, physical & digital resources